Technology
Biocept…Innovative in Technology
Biocept, an emerging biotechnology leader, has developed the patented Cell Enrichment and Extraction™ (CEE) technology that utilizes the company’s proprietary microfluidic system to capture rare cells, including circulating tumor cells (CTCs) in blood and disseminated tumor cells (DTCs) in bone marrow.
Biocept…Tailoring Treatment More Effectively
Captured CTCs and DTCs remain suitable for molecular diagnosis by fluorescent in situ hybridization (FISH) or by a variety of molecular analyses (e.g., PCR) after extraction of the DNA. Molecular analysis of the cells may indicate which patients will respond to designated therapies and provide physicians the information to personalize treatment for patients.
Biocept…Impacting the Lives of Cancer Patients
Biocept is developing a new, powerful class of specialized laboratory tests for personalized medicine in early detection, diagnosis and monitoring of various solid tumor cancers. Biocept is dedicated to providing actionable information to the oncologist to assist in predicting the outcome of medical treatments for the patient and improving quality of life.